ST-segment Elevation Not Associated With Acute Cardiac Necrosis (LESTONNAC)
LESTONNAC
LESTONNAC Study: Observed ST Elevation Does Not Require Acute Cardiac Necrosis
1 other identifier
observational
420
1 country
7
Brief Summary
Patients with chest pain and persistent ST segment elevation (STE) may not have acute coronary occlusions or serum troponin curves suggestive of acute necrosis. Our objective is the validation and cost-effectiveness analysis of a diagnostic model assisted by artificial intelligence (AI). Our hypothesis is that an AI analysis of the surface electrocardiogram allows a better distinction of patients with STE due to acute myocardial ischemia, from those with another etiology. This is a prospective multicenter study with two groups of patients with STE: I) coronary arteries without significant lesions and without serum troponin curve suggestive of acute necrosis, II) myocardial infarction with acute coronary occlusion. A manual centralized electrocardiographic analysis and another by AI algorithms will be performed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2022
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 25, 2022
CompletedFirst Submitted
Initial submission to the registry
December 20, 2022
CompletedFirst Posted
Study publicly available on registry
January 19, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 25, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 24, 2024
CompletedMarch 6, 2024
March 1, 2024
1.5 years
December 20, 2022
March 4, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Clinical validation of a screening model assisted by AI
The detection performance of acute myocardial ischemia will be evaluated for the AI platform in comparison to standard manual analysis.
6 months after the last enrolled patient
Secondary Outcomes (1)
Cost-effectiveness analysis of a screening model assisted by AI
1 year after the last enrolled patient
Study Arms (2)
STE patients
Patients with ST segment elevation (STE) and coronary arteries without significant lesions and without a serum troponin curve suggestive of acute necrosis (group without acute myocardial necrosis).
STEMI patients
Patients with ST segment elevation with acute occlusion of at least one epicardial coronary artery and TIMI flow 0 or I (group with acute myocardial necrosis of ischemic origin), that meet the definition of myocardial infarction (STEMI) with an acute cardiac necrosis curve verified by measurement of troponin I or troponin T.
Interventions
A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.
Eligibility Criteria
Patients going to the hospital with suspected symptoms of myocardial infarction and ST segment elevation in the electrocardiogram.
You may qualify if:
- Age≥18 years.
- Chest pain or symptoms suggestive of myocardial ischemia.
- STE at point J in the12-lead electrocardiogram prior to activation of the infarction code in two contiguous leads ≥0.1 mV, in V2 and V3 ≥0.2 mV.
- Signature of informed consent.
You may not qualify if:
- Left bundle branch block.
- Acute cardiac necrosis in the absence of significant epicardial coronary artery stenosis \>70% (vasospasm, takotsubo stress cardiomyopathy, myocarditis, coronary artery dissection, acute myocardial infarction without obstructive coronary lesions - MINOCA).
- STE≤0.1 mV with pathologic Q wave suggestive of previous chronic infarction.
- Severe anemia (hemoglobin \<8.0 g/dl).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Idoven 1903 S.L.lead
- Hospital General Universitario Gregorio Marañoncollaborator
- Spanish Society of Cardiologycollaborator
Study Sites (7)
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320, Spain
Hospital de Basurto
Bilbao, Vizcaya, 48013, Spain
Hospital Vall D' Hebron
Barcelona, 08035, Spain
Idoven
Madrid, 28002, Spain
Servicio Cardiología Hospital Universitario Gregorio Marañón
Madrid, 28007, Spain
Hospital Clínico San Carlos
Madrid, 28040, Spain
Hospital Clínico Universitario de Valladolid
Valladolid, 47003, Spain
Related Publications (3)
Martinez-Selles M, Bueno H, Sacristan A, Estevez A, Ortiz J, Gallego L, Fernandez-Aviles F. Chest pain in the emergency department: incidence, clinical characteristics and risk stratification. Rev Esp Cardiol. 2008 Sep;61(9):953-9. English, Spanish.
PMID: 18775237BACKGROUNDLillo-Castellano JM, Gonzalez-Ferrer JJ, Marina-Breysse M, Martinez-Ferrer JB, Perez-Alvarez L, Alzueta J, Martinez JG, Rodriguez A, Rodriguez-Perez JC, Anguera I, Vinolas X, Garcia-Alberola A, Quintanilla JG, Alfonso-Almazan JM, Garcia J, Borrego L, Canadas-Godoy V, Perez-Castellano N, Perez-Villacastin J, Jimenez-Diaz J, Jalife J, Filgueiras-Rama D. Personalized monitoring of electrical remodelling during atrial fibrillation progression via remote transmissions from implantable devices. Europace. 2020 May 1;22(5):704-715. doi: 10.1093/europace/euz331.
PMID: 31840163BACKGROUNDQuartieri F, Marina-Breysse M, Pollastrelli A, Paini I, Lizcano C, Lillo-Castellano JM, Grammatico A. Artificial intelligence augments detection accuracy of cardiac insertable cardiac monitors: Results from a pilot prospective observational study. Cardiovasc Digit Health J. 2022 Aug 4;3(5):201-211. doi: 10.1016/j.cvdhj.2022.07.071. eCollection 2022 Oct.
PMID: 36310681BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Manuel Martínez-Sellés, MD
Hospital Universitario Gregorio Marañón
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 20, 2022
First Posted
January 19, 2023
Study Start
July 25, 2022
Primary Completion
January 25, 2024
Study Completion
July 24, 2024
Last Updated
March 6, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share